ATC Group: G04BD02 Flavoxate

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04BD02 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04B Other urologicals, incl. antispasmodics
4 G04BD Urinary antispasmodics
5 G04BD02 Flavoxate

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.8 g

Active ingredients in G04BD02

Active Ingredient Description
Flavoxate

Flavoxate is an antispasmodic selective to the urinary tract. Flavoxate has been shown to have a direct antispasmodic action on smooth muscle fibres.

Related product monographs

Title Information Source Document Type  
BLADURIL Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
URISPAS Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.